Unió Europea - suec - EMA (European Medicines Agency)

viatris limited - pirfenidon - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - immunsuppressiva - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Unió Europea - suec - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - läkemedel som används vid diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 och 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Unió Europea - suec - EMA (European Medicines Agency)

viatris limited - klopidogrelbesilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotiska medel - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segmentet höjd akut hjärtinfarkt, i kombination med asa i medicinskt behandlade patienter berättigade till trombolysbehandling. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. för ytterligare information hänvisas till avsnitt 5.

Suècia - suec - Läkemedelsverket (Medical Products Agency)

viatris limited - metylfenidathydroklorid - depottablett - 18 mg - metylfenidathydroklorid 14,22 mg aktiv substans; metylfenidathydroklorid 3,78 mg aktiv substans; sockersfärer hjälpämne - metylfenidat

Suècia - suec - Läkemedelsverket (Medical Products Agency)

viatris limited - metylfenidathydroklorid - depottablett - 36 mg - sockersfärer hjälpämne; metylfenidathydroklorid 7,56 mg aktiv substans; metylfenidathydroklorid 28,44 mg aktiv substans - metylfenidat

Suècia - suec - Läkemedelsverket (Medical Products Agency)

viatris limited - metylfenidathydroklorid - depottablett - 54 mg - sockersfärer hjälpämne; metylfenidathydroklorid 11,34 mg aktiv substans; metylfenidathydroklorid 42,66 mg aktiv substans - metylfenidat

Suècia - suec - Läkemedelsverket (Medical Products Agency)

viatris limited - metylfenidathydroklorid - depottablett - 27 mg - sockersfärer hjälpämne; metylfenidathydroklorid 5,67 mg aktiv substans; metylfenidathydroklorid 21,33 mg aktiv substans

Suècia - suec - Läkemedelsverket (Medical Products Agency)

viatris limited - atorvastatinkalciumtrihydrat - filmdragerad tablett - 10 mg - laktos (vattenfri) hjälpämne; atorvastatinkalciumtrihydrat 10,844 mg aktiv substans - atorvastatin

Suècia - suec - Läkemedelsverket (Medical Products Agency)

viatris limited - atorvastatinkalciumtrihydrat - filmdragerad tablett - 20 mg - atorvastatinkalciumtrihydrat 21,688 mg aktiv substans; laktos (vattenfri) hjälpämne - atorvastatin

Suècia - suec - Läkemedelsverket (Medical Products Agency)

viatris limited - atorvastatinkalciumtrihydrat - filmdragerad tablett - 40 mg - laktos (vattenfri) hjälpämne; atorvastatinkalciumtrihydrat 43,376 mg aktiv substans - atorvastatin